IL150265A0 - Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds - Google Patents

Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds

Info

Publication number: IL150265A0
Authority: IL; Israel
Prior art keywords: hiv protease; inhibiting compounds; protease inhibiting; pharmaceutical formulations; improved pharmaceutical
Prior art date: 2000-01-19

Application number

IL15026500A

Other languages

English (en)

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-19

Filing date

2000-12-01

Publication date

2002-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL150265(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-01 Application filed by Abbott Lab filed Critical Abbott Lab

2002-12-01 Publication of IL150265A0 publication Critical patent/IL150265A0/xx

Links

150000001875 compounds Chemical class 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
108091005804 Peptidases Proteins 0.000 title 1
239000004365 Protease Substances 0.000 title 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
108010010369 HIV Protease Proteins 0.000 abstract 1
150000004668 long chain fatty acids Chemical class 0.000 abstract 1
150000004667 medium chain fatty acids Chemical class 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)

IL15026500A 2000-01-19 2000-12-01 Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds IL150265A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48773900A	2000-01-19	2000-01-19
PCT/US2000/032771 WO2001052821A1 (fr)	2000-01-19	2000-12-01	Formulations pharmaceutiques ameliorees

Publications (1)

Publication Number	Publication Date
IL150265A0 true IL150265A0 (en)	2002-12-01

Family

ID=23936923

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL15026500A IL150265A0 (en)	2000-01-19	2000-12-01	Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds
IL150265A IL150265A (en)	2000-01-19	2002-06-17	Pharmaceutical compounds including ritanavir and an organic solvent containing long-chain fatty acid and propylene glycol

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL150265A IL150265A (en)	2000-01-19	2002-06-17	Pharmaceutical compounds including ritanavir and an organic solvent containing long-chain fatty acid and propylene glycol

Country Status (25)

Country	Link
EP (3)	EP1917958B1 (fr)
JP (1)	JP4769400B2 (fr)
KR (1)	KR100861885B1 (fr)
CN (1)	CN100536833C (fr)
AT (1)	ATE395049T1 (fr)
AU (2)	AU1940501A (fr)
BG (1)	BG66112B1 (fr)
BR (1)	BR0011864A (fr)
CA (1)	CA2395987C (fr)
CY (3)	CY1108197T1 (fr)
CZ (1)	CZ304118B6 (fr)
DE (1)	DE60038899D1 (fr)
DK (3)	DK2269591T3 (fr)
ES (3)	ES2676151T3 (fr)
HU (1)	HU229778B1 (fr)
IL (2)	IL150265A0 (fr)
MX (1)	MXPA02007097A (fr)
NO (1)	NO331400B1 (fr)
NZ (1)	NZ519724A (fr)
PT (3)	PT2269591T (fr)
SI (3)	SI1248600T1 (fr)
SK (1)	SK287143B6 (fr)
TR (1)	TR201809435T4 (fr)
WO (1)	WO2001052821A1 (fr)
ZA (1)	ZA200205109B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2359945C (fr)	1999-11-12	2011-04-26	Abbott Laboratories	Inhibiteurs de cristallisation dans une dispersion solide
US7364752B1 (en)	1999-11-12	2008-04-29	Abbott Laboratories	Solid dispersion pharamaceutical formulations
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
GB0615211D0 (en) *	2006-07-31	2006-09-06	Ge Healthcare Uk Ltd	Asymmetric flouro-substituted polymethine dyes
WO2009019661A1 (fr) *	2007-08-07	2009-02-12	Ranbaxy Laboratories Limited	Procédé de préparation de lopinavir amorphe
WO2012164575A2 (fr)	2011-05-27	2012-12-06	Hetero Research Foundation	Ritonavir amorphe co-précipité
GB201808563D0 (en)	2018-05-24	2018-07-11	Univ Manchester	Treatments
GB201808564D0 (en)	2018-05-24	2018-07-11	Douglas Pharmaceuticals Ltd	Treatments
GB201907305D0 (en)	2019-05-23	2019-07-10	Douglas Pharmaceuticals Ltd	Treatment of conditions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US594836A (en) *		1897-11-30		Corner-brace
US5354866A (en)	1989-05-23	1994-10-11	Abbott Laboratories	Retroviral protease inhibiting compounds
US5552558A (en)	1989-05-23	1996-09-03	Abbott Laboratories	Retroviral protease inhibiting compounds
GB8927913D0 (en)	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
EP0813868B1 (fr)	1990-11-19	2005-06-01	Monsanto Company	Inhibiteurs de protéases rétrovirales
CA2056911C (fr)	1990-12-11	1998-09-22	Yuuichi Nagano	Inhibiteurs de la protease de vih
EP0532466A3 (en)	1991-09-12	1993-06-16	Ciba-Geigy Ag	Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
BR9206623A (pt)	1991-10-11	1995-05-02	Du Pont Merck Pharma	Uréias cíclicas e análogas úteis como inibidoras da protease retroviral
US5413999A (en)	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
ATE163926T1 (de)	1991-11-08	1998-03-15	Merck & Co Inc	Hiv-protease-inhibitoren verwendbar in der aids- behandlung
EP0560268B1 (fr)	1992-03-13	1995-01-04	Bio-Mega/Boehringer Ingelheim Research Inc.	Dérivés de l'acide pipécolinic comme inhibiteurs de HIV-protéase
WO1993023368A1 (fr)	1992-05-20	1993-11-25	G.D. Searle & Co.	Composes d'hydroxyethylamine contenant de l'uree utilises comme inhibiteurs de proteases retrovirales
US5559256A (en)	1992-07-20	1996-09-24	E. R. Squibb & Sons, Inc.	Aminediol protease inhibitors
IS2334B (is)	1992-09-08	2008-02-15	Vertex Pharmaceuticals Inc., (A Massachusetts Corporation)	Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en)	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
EP1302468B1 (fr)	1992-12-29	2008-12-17	Abbott Laboratories	Procédés et intermédiaires pour la préparation d'inhibiteurs de protéase rétrovirale
AU7518694A (en)	1993-08-20	1995-03-21	G.D. Searle & Co.	Retroviral protease inhibitors and combinations thereof
IL110752A (en) *	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
GB9319129D0 (en) *	1993-09-15	1993-11-03	Dowelanco Ltd	Storage and dilution of stable aqueous dispersions
US5559158A (en)	1993-10-01	1996-09-24	Abbott Laboratories	Pharmaceutical composition
US5491253A (en)	1993-10-22	1996-02-13	Abbott Laboratories	Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) *	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129871A (en)	1994-05-06	2003-11-23	Pharmacia & Upjohn Inc	Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5567823A (en)	1995-06-06	1996-10-22	Abbott Laboratories	Process for the preparation of an HIV protease inhibiting compound
US6037157A (en)	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
EP1295874A3 (fr) *	1995-12-13	2003-04-02	Abbott Laboratories	Composés inhibant la protéase rétrovirale
US6160122A (en)	1996-06-28	2000-12-12	Abbott Laboratories	Process for the preparation of a disubstituted thiazole
ZA9710071B (en)	1996-11-21	1998-05-25	Abbott Lab	Pharmaceutical composition.
ATE332132T1 (de) *	1999-06-04	2006-07-15	Abbott Lab	Verbesserte arzneizubereitungen enthaltend ritonavir

2000
- 2000-12-01 DK DK10177365.3T patent/DK2269591T3/en active
- 2000-12-01 KR KR1020027009316A patent/KR100861885B1/ko not_active Ceased
- 2000-12-01 EP EP07121429A patent/EP1917958B1/fr not_active Revoked
- 2000-12-01 NZ NZ519724A patent/NZ519724A/en not_active IP Right Cessation
- 2000-12-01 WO PCT/US2000/032771 patent/WO2001052821A1/fr not_active Ceased
- 2000-12-01 AU AU19405/01A patent/AU1940501A/en not_active Abandoned
- 2000-12-01 CN CNB008184798A patent/CN100536833C/zh not_active Expired - Lifetime
- 2000-12-01 ES ES10177365.3T patent/ES2676151T3/es not_active Expired - Lifetime
- 2000-12-01 EP EP10177365.3A patent/EP2269591B1/fr not_active Revoked
- 2000-12-01 SI SI200030994T patent/SI1248600T1/sl unknown
- 2000-12-01 AT AT00982360T patent/ATE395049T1/de active
- 2000-12-01 CZ CZ20022663A patent/CZ304118B6/cs not_active IP Right Cessation
- 2000-12-01 TR TR2018/09435T patent/TR201809435T4/tr unknown
- 2000-12-01 CA CA002395987A patent/CA2395987C/fr not_active Expired - Lifetime
- 2000-12-01 ES ES07121429T patent/ES2387579T3/es not_active Expired - Lifetime
- 2000-12-01 HU HU0302070A patent/HU229778B1/hu not_active IP Right Cessation
- 2000-12-01 EP EP00982360A patent/EP1248600B1/fr not_active Revoked
- 2000-12-01 ES ES00982360T patent/ES2304990T3/es not_active Expired - Lifetime
- 2000-12-01 MX MXPA02007097A patent/MXPA02007097A/es active IP Right Grant
- 2000-12-01 DK DK07121429.0T patent/DK1917958T3/da active
- 2000-12-01 JP JP2001552869A patent/JP4769400B2/ja not_active Expired - Lifetime
- 2000-12-01 DE DE60038899T patent/DE60038899D1/de not_active Expired - Lifetime
- 2000-12-01 DK DK00982360T patent/DK1248600T3/da active
- 2000-12-01 SK SK1110-2002A patent/SK287143B6/sk not_active IP Right Cessation
- 2000-12-01 PT PT101773653T patent/PT2269591T/pt unknown
- 2000-12-01 PT PT07121429T patent/PT1917958E/pt unknown
- 2000-12-01 PT PT00982360T patent/PT1248600E/pt unknown
- 2000-12-01 SI SI200031095T patent/SI2269591T1/en unknown
- 2000-12-01 SI SI200031073T patent/SI1917958T1/sl unknown
- 2000-12-01 IL IL15026500A patent/IL150265A0/xx unknown
- 2000-12-01 BR BR0011864-8A patent/BR0011864A/pt not_active Application Discontinuation
2002
- 2002-06-17 IL IL150265A patent/IL150265A/en active IP Right Grant
- 2002-06-25 ZA ZA200205109A patent/ZA200205109B/xx unknown
- 2002-07-18 NO NO20023455A patent/NO331400B1/no not_active Application Discontinuation
- 2002-08-02 BG BG106976A patent/BG66112B1/bg unknown
2006
- 2006-11-07 AU AU2006235895A patent/AU2006235895B2/en not_active Revoked
2008
- 2008-07-16 CY CY20081100740T patent/CY1108197T1/el unknown
2012
- 2012-08-07 CY CY20121100711T patent/CY1112995T1/el unknown
2018
- 2018-07-03 CY CY20181100697T patent/CY1120408T1/el unknown

Also Published As

Publication number	Publication date
MXPA02007097A (es)	2003-01-28
KR20020082210A (ko)	2002-10-30
EP2269591B1 (fr)	2018-04-04
JP4769400B2 (ja)	2011-09-07
BG66112B1 (bg)	2011-05-31
CA2395987A1 (fr)	2001-07-26
DK1917958T3 (da)	2012-09-24
ATE395049T1 (de)	2008-05-15
CA2395987C (fr)	2009-12-22
EP1248600B1 (fr)	2008-05-14
SI2269591T1 (en)	2018-08-31
IL150265A (en)	2015-02-26
JP2003533435A (ja)	2003-11-11
PL361396A1 (en)	2004-10-04
AU2006235895A1 (en)	2006-11-30
AU2006235895B2 (en)	2009-08-13
CZ304118B6 (cs)	2013-11-06
BG106976A (bg)	2003-05-30
EP1917958A3 (fr)	2008-08-27
HK1120213A1 (en)	2009-03-27
CZ20022663A3 (cs)	2002-11-13
HU229778B1 (hu)	2014-07-28
SK287143B6 (sk)	2010-01-07
ES2304990T3 (es)	2008-11-01
CY1108197T1 (el)	2014-02-12
ZA200205109B (en)	2003-10-31
NO20023455D0 (no)	2002-07-18
SK11102002A3 (sk)	2002-12-03
HUP0302070A3 (en)	2007-02-28
NO20023455L (no)	2002-09-18
CN1424907A (zh)	2003-06-18
NZ519724A (en)	2004-07-30
TR201809435T4 (tr)	2018-07-23
EP2269591A3 (fr)	2011-07-27
ES2387579T3 (es)	2012-09-26
WO2001052821A1 (fr)	2001-07-26
KR100861885B1 (ko)	2008-10-09
NO331400B1 (no)	2011-12-19
BR0011864A (pt)	2004-07-20
DK2269591T3 (en)	2018-07-16
DK1248600T3 (da)	2008-09-08
ES2676151T3 (es)	2018-07-17
PT2269591T (pt)	2018-07-09
EP1917958A2 (fr)	2008-05-07
CN100536833C (zh)	2009-09-09
EP1917958B1 (fr)	2012-06-13
SI1917958T1 (sl)	2012-10-30
DE60038899D1 (de)	2008-06-26
SI1248600T1 (sl)	2008-08-31
PT1248600E (pt)	2008-08-25
AU1940501A (en)	2001-07-31
HUP0302070A2 (hu)	2003-09-29
CY1112995T1 (el)	2016-04-13
EP1248600A1 (fr)	2002-10-16
PT1917958E (pt)	2012-08-16
EP2269591A2 (fr)	2011-01-05
CY1120408T1 (el)	2019-07-10

Publication	Publication Date	Title
BG106239A (en)	2002-08-30	Improved pharmaceutical formulations
CY1120408T1 (el)	2019-07-10	Βελτιωμενες φαρμακοτεχνικες μορφες
HUP0301405A3 (en)	2006-02-28	Compositions containing therapeutically active components having enhanced solubility
MXPA02012891A (es)	2003-10-24	Composiciones farmaceuticas de agentes estrogenicos.
HUP0300720A3 (en)	2009-04-28	Serine protease inhibitors, pharmaceutical compositions containing them and their use
AU2002222567A1 (en)	2002-08-15	Composition improved in solubility or oral absorbability
HUP0400832A3 (en)	2004-10-28	New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
PL350075A1 (en)	2002-11-04	Taxane formulations having improved solubility
RU2001126719A (ru)	2004-02-20	Дигетерозамещенные ингибиторы металлопротеазы
IL145635A0 (en)	2002-06-30	Taxane formulations having improved solubility
HUP0303673A3 (en)	2010-04-28	Piperidine derivatives and pharmaceutical compositions containing these derivatives as the active ingredient
IL126185A0 (en)	1999-05-09	Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
IT1318962B1 (it)	2003-09-19	Procedimento per l'invio di messaggi pubblicitari direttamente adutenti.
SE0001916D0 (sv)	2000-05-23	Novel formulation
IL156174A (en)	2008-11-03	1,2,4-oxadiazole derivatives and pharmaceutical compositions containing them
IT1318654B1 (it)	2003-08-27	Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.
AU7384700A (en)	2002-04-02	Pharmaceutical compositions for rectal and vaginal administration
IL136321A0 (en)	2001-05-20	Pharmaceutical compositions comprising cannabidiol derivatives
GB0015361D0 (en)	2000-08-16	Improvements in pharmaceutical compositions
IT1320768B1 (it)	2003-12-10	Composizioni farmaceutiche ad elevata attivita' antiossidante verso iradicali liberi.